European Union Reaches Provisional Deal on Critical Medicines Act

The European Union reached a provisional deal to strengthen the supply of essential medicines such as antibiotics, insulin, vaccines and painkillers and to avoid shortages by boosting domestic production and reducing reliance on imports. Known as the Critical Medicines Act, the initiative seeks to prevent the kinds of drug shortages seen during the Covid-19 pandemic.

The proposal specifically targets supply-chain weaknesses for more than 200 medicines considered critical to the region’s health security, including treatments for rare diseases. The agreement was announced on May 12, 2026. Officials said the measure is intended to reduce vulnerabilities in the supply of medicines and their ingredients.

Statement on the Agreement “With today’s agreement, we are taking practical action to reduce our vulnerabilities, diversify supply chains and strengthen Europe’s capacity to produce critical medicines and their ingredients closer to home,” said Neophytos Charalambides, the health minister for Cyprus, in a statement.

The provisional deal comes after years of concern over dependence on imported medicines and active pharmaceutical ingredients, much of which originates outside the European Union. By encouraging local production, the Critical Medicines Act is designed to improve the region’s ability to maintain stable supplies during future health emergencies or disruptions in global trade.